J Rheum Dis.  2016 Jun;23(3):139-140. 10.4078/jrd.2016.23.3.139.

Lung Disease in Rheumatoid Arthritis

• Lee JS
• Lee EY

• KMID: 2326727
• DOI: http://doi.org/10.4078/jrd.2016.23.3.139

Abstract

No abstract available.

MeSH Terms

Arthritis, Rheumatoid*
Lung Diseases*
Lung*

Reference

1. Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respir Rev. 2015; 24:1–16.

2. Wang T, Zheng XJ, Liang BM, Liang ZA. Clinical features of rheumatoid arthritis-associated interstitial lung disease. Sci Rep. 2015; 5:14897.

3. Wang T, Zheng XJ, Ji YL, Liang ZA, Liang BM. Tumour markers in rheumatoid arthritis-associated interstitial lung disease. Clin Exp Rheumatol. 2016; May 19 [Epub]. PMID: 27213221.

4. Ota M, Iwasaki Y, Harada H, Sasaki O, Nagafuchi Y, Nakachi S, et al. Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2016; 1–7.

5. Oka S, Furukawa H, Shimada K, Sugii S, Hashimoto A, Komiya A, et al. Association of human leukocyte antigen alleles with chronic lung diseases in rheumatoid arthritis. Rheumatology (Oxford). 2016 Apr 5; [Epub].DOI: DOI: 10.1093/ rheumatology/kew025.

6. Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Leflunomide use and risk of lung disease in Rheumatoid arthritis: a systematic literature review and metaanalysis of randomized controlled trials. J Rheumatol. 2016; 43:855–60.

7. Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-con-trol study. Rheumatol Int. 2016; 36:881–9.

8. Kim JW, Lee H, Hwang JH, Park SH, Lee HS, Kim SK, et al. Factors associated with airway disease and interstitial lung disease in rheumatoid arthritis. J Rheum Dis. 2016; 23:101–8.

9. Quirke AM, Perry E, Cartwright A, Kelly C, De Soyza A, Eggleton P, et al. Bronchiectasis is a model for chronic bacterial infection inducing autoimmunity in rheumatoid arthritis. Arthritis Rheumatol. 2015; 67:2335–42.

10. Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014; 73:1487–94.

11. Damgaard D, Friberg Bruun Nielsen M, Quisgaard Gaunsbaek M, Palarasah Y, Svane-Knudsen V, Nielsen CH. Smoking is associated with increased levels of extracellular peptidylarginine deiminase 2 (PAD2) in the lungs. Clin Exp Rheumatol. 2015; 33:405–8.

12. Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014; 66:803–12.

13. Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ. 2015; 350:h1269.

14. Jani M, Hirani N, Matteson EL, Dixon WG. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol. 2014; 10:284–94.

15. Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015; 67:28–38.

16. Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, et al. Detection of Rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015; 191:1403–12.